The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the successful reclassification of Nasonex Allergy Control 0.05% Nasal Spray following a public consultation. The spray, which will soon be available over the counter in pharmacies, is used to treat symptoms of allergic rhinitis. 

The decision follows the POM to P reclassification granted to Maloff Protect last week. MHRA commented that is “committed to involving people in their healthcare, and to widen access to medicines for the benefit of public health when it is safe to do”.

Recommended

Gearing up for the flu vaccination 2018-19

Information and promotional resources to support the 2018-19 flu vaccination programme are becoming available, including...

Love Your Liver week: deaths from liver disease soaring

Some 60,000 adults in the UK have liver disease, yet almost 75 per cent of these don’t know they are affected